ZC3HC1 acts as a dosage-sensitive modulator of SMC phenotype. Partial reduction promotes a synthetic, proliferative state and neointima formation, while complete loss induces a quiescent phenotype. These findings provide mechanistic insight into the paradoxical clinical associations of the rs11556924-T allele and identify ZC3HC1 as a potential target for modulating SMC phenotypes in vascular disease.
Aherrahrou et al. (Thu,) studied this question.